Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

By LabMedica International staff writers
Posted on 23 Apr 2024

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. More...

Early MS symptoms, including dizziness, spasms, and fatigue, often resemble other conditions, complicating diagnosis, which heavily relies on detailed brain MRI evaluations. MS can severely impair motor control, but advancements in treatment can slow down its progression and help maintain functions such as walking. Notably, around 10% of MS patients begin producing a distinctive set of antibodies against their own proteins years before symptoms appear. These autoantibodies have been found to bind to both human cells and common pathogens, possibly explaining why immune attacks on the brain and spinal cord occur in MS. Now, researchers have identified a unique autoantibody signature in about 10% of MS patients that appears years before the onset of clinical symptoms, raising hopes for early detection via a simple blood test and earlier treatment initiation.

Utilizing the U.S. Department of Defense Serum Repository, which includes data from over ten million individuals, a team from the University of California, San Francisco (UCSF, San Francisco, CA, USA) and the University of North Carolina at Charlotte (Charlotte, NC, USA) performed whole-proteome autoantibody profiling on samples from hundreds of MS patients both before and after they experienced symptoms. They identified a specific group of patients who exhibited a recognizable pattern of autoantibodies long before any clinical symptoms of MS appeared, accompanied by increased levels of serum neurofilament light (sNfL), which indicates early neuroaxonal damage.

This autoantibody signature was also validated using samples from another MS cohort, confirming its strong specificity for patients diagnosed with MS. This breakthrough could lead to the development of antigen-specific biomarkers for high-risk individuals with clinically or radiologically isolated neuroinflammatory syndromes. While many questions about MS remain—from the triggers of the immune response in certain patients to the disease's progression in the majority who do not exhibit these autoantibodies—researchers are optimistic that they have found a vital early indicator of its development.

"This study sheds light on the preclinical phase of MS and provides a promising avenue for early detection and intervention. Identifying patients at high risk of developing MS before symptom onset could revolutionize patient care and treatment strategies," said Danillo Augusto, Ph.D., an assistant professor in biology at the University of North Carolina at Charlotte.

“Over the last few decades, there's been a move in the field to treat MS earlier and more aggressively with newer, more potent therapies,” said UCSF neurologist Michael Wilson, MD. “A diagnostic result like this makes such early intervention more likely, giving patients hope for a better life.”

Related Links:
UCSF
UNC Charlotte  


New
Gold Member
Hematology Analyzer
Medonic M32B
Portable Electronic Pipette
Mini 96
New
Urine Chemistry Control
Dropper Urine Chemistry Control
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.